Larimar Therapeutics, Inc. (LRMR) stock
LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.99−0.01 (-0.33%)
Close on Nov 17, 2026Market cap $310.61MP/E –Yield –
Larimar Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Larimar Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$178.99M. For fiscal 2025 it was -$172.50M. The highest annual figure on record is -$13.78M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$172.50M | – |
| FY2024 | Dec 31, 2024 | -$90.89M | – |
| FY2023 | Dec 31, 2023 | -$41.76M | – |
| FY2022 | Dec 31, 2022 | -$36.53M | – |
| FY2021 | Dec 31, 2021 | -$50.47M | – |
| FY2020 | Dec 31, 2020 | -$42.80M | – |
| FY2019 | Dec 31, 2019 | -$23.21M | – |
| FY2018 | Dec 31, 2018 | -$61.12M | – |
| FY2017 | Dec 31, 2017 | -$53.00M | – |
| FY2016 | Dec 31, 2016 | -$58.23M | – |
| FY2015 | Dec 31, 2015 | -$73.81M | – |
| FY2014 | Dec 31, 2014 | -$35.53M | – |
| FY2013 | Dec 31, 2013 | -$13.78M | – |
| FY2012 | Dec 31, 2012 | -$13.79M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$34.35M | – |
| Q1 FY2026 | Mar 31, 2026 | -$31.12M | – |
| Q4 FY2025 | Dec 31, 2025 | -$64.02M | – |
| Q3 FY2025 | Sep 30, 2025 | -$49.50M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.79M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.19M | – |
| Q4 FY2024 | Dec 31, 2024 | -$31.29M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$24.60M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.73M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.16M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.34M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.64M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.44M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.51M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.69M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.89M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.73M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.40M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.34M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.40M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.67M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.16M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.63M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.70M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.28M | – |
| Q4 FY2018 | Dec 31, 2018 | -$14.69M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.17M | – |
| Q2 FY2018 | Jun 30, 2018 | -$15.56M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.70M | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.36M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.84M | – |
| Q2 FY2017 | Jun 30, 2017 | -$13.54M | – |
| Q1 FY2017 | Mar 31, 2017 | -$13.27M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.48M | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.83M | – |
See a number that looks wrong?